The development of potential new fluorine-18 labelled radiotracers for imaging the GABA(A) receptor.

[1]  A. Thiel,et al.  Improved work-up procedure for the production of [(18)F]flumazenil and first results of its use with a high-resolution research tomograph in human stroke. , 2009, Nuclear medicine and biology.

[2]  Christer Halldin,et al.  [18F]Flumazenil binding to central benzodiazepine receptor studies by PET – Quantitative analysis and comparisons with [11C]flumazenil – , 2009, NeuroImage.

[3]  M. Grégoire,et al.  In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  L. Goldstein,et al.  Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: An (11C)‐flumazenil PET study , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[5]  M. Sasaki,et al.  Pre-surgical identification of epileptogenic areas in temporal lobe epilepsy by 123I-iomazenil SPECT: A comparison with IMP SPECT and FDG PET , 2006, Nuclear medicine communications.

[6]  S. Jakobsen,et al.  Synthesis, radiolabeling and in vivo evaluation of [11C]RAL-01, a potential phosphodiesterase 5 radioligand. , 2006, Nuclear medicine and biology.

[7]  Shinya Kagawa,et al.  Selective neuronal damage and borderzone infarction in carotid artery occlusive disease: a 11C-flumazenil PET study. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Seung Jin Lee,et al.  Biological properties of 2'-[18F]fluoroflumazenil for central benzodiazepine receptor imaging. , 2005, Nuclear medicine and biology.

[9]  Christer Halldin,et al.  Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. , 2005, Nuclear medicine and biology.

[10]  A. Thiel,et al.  Probability of Cortical Infarction Predicted by Flumazenil Binding and Diffusion-Weighted Imaging Signal Intensity: A Comparative Positron Emission Tomography/Magnetic Resonance Imaging Study in Early Ischemic Stroke , 2004, Stroke.

[11]  Alexander Hammers,et al.  Flumazenil positron emission tomography and other ligands for functional imaging. , 2004, Neuroimaging clinics of North America.

[12]  Wolfgang Wadsak,et al.  Biological evaluation of 2'-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. , 2004, Nuclear medicine and biology.

[13]  Dong Soo Lee,et al.  Novel one-pot one-step synthesis of 2'-[(18)F]fluoroflumazenil (FFMZ) for benzodiazepine receptor imaging. , 2003, Nuclear medicine and biology.

[14]  Victor W. Pike,et al.  Imaging the GABA-Benzodiazepine Receptor Subtype Containing the α5-Subunit In Vivo with [11C]Ro15 4513 Positron Emission Tomography , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  Hans-Georg Buchholz,et al.  [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors , 2001, European Journal of Nuclear Medicine.

[16]  D. Labar,et al.  Biodistribution, binding specificity and metabolism of [18F]fluoroethylflumazenil in rodents. , 2001, Nuclear medicine and biology.

[17]  W. Heiss,et al.  Early [(11)C]Flumazenil/H(2)O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy. , 2000, Stroke.

[18]  Xiaohui He,et al.  Pharmacophore/Receptor Models for GABAA/BzR Subtypes (α1β3γ2, α5β3γ2, and α6β3γ2) via a Comprehensive Ligand-Mapping Approach , 2000 .

[19]  O Muzik,et al.  [11C]flumazenil PET: activity images versus parametric images for the detection of neocortical epileptic foci. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Ticku,et al.  An update on GABAA receptors , 1999, Brain Research Reviews.

[21]  W. Sieghart,et al.  Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. , 1995, Pharmacological reviews.

[22]  N L Foster,et al.  Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. , 1995, Archives of neurology.

[23]  P. Skolnick,et al.  Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors. , 1993, Journal of medicinal chemistry.

[24]  I Savic,et al.  Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[25]  S M Moerlein,et al.  Binding of 5-(2'-[18F]fluoroethyl)flumazenil to central benzodiazepine receptors measured in living baboon by positron emission tomography. , 1992, European journal of pharmacology.

[26]  G. Sedvall,et al.  [11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding , 1992, Psychopharmacology.

[27]  G. Sedvall,et al.  IN-VIVO DEMONSTRATION OF REDUCED BENZODIAZEPINE RECEPTOR BINDING IN HUMAN EPILEPTIC FOCI , 1988, The Lancet.

[28]  D Comar,et al.  Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. , 1984, The International journal of applied radiation and isotopes.

[29]  K. Lindahl-Kiessling,et al.  USE AND ABUSE OF ELECTROENCEPHALOGRAPHY. , 1964, Lancet.

[30]  S. Stone-Elander,et al.  11C-labelling of Ro 15-1788 in two different positions, and also 11C-labelling of its main metabolite Ro 15-3890, for PET studies of benzodiazepine receptors. , 1988, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[31]  L. Goldfrank.  Goldfrank's Toxicologic emergencies , 1986 .

[32]  L. Eriksson,et al.  Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. , 1985, Journal of psychiatric research.